Zobrazeno 1 - 10
of 547
pro vyhledávání: ''
Autor:
Nancy Chan, Jiuping Ji, Antoinette R. Tan, Janice M. Mehnert, Alice P. Chen, Jan H. Beumer, Mansi Shah, Joseph Aisner, Murugesan Gounder, Jyoti Malhotra, Rebecca A. Moss, Yong Lin, Brian F. Kiesel, Hongxia Lin, Mark N. Stein, Michael P. Kane
Publikováno v:
Cancer Chemother Pharmacol
Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus
Autor:
Raphael Teipel, Susanne Quick, Stephan Richter, Holger Knoth, Theresa Kretschmann, Frank Kroschinsky, Christoph Röllig, Ekaterina Balaian, Nael Alakel, Martin Bornhäuser, Sandra Heuschkel, Malte von Bonin, Simone von Bonin
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose High-dose methotrexate (HDMTX)-associated acute kidney injury with delayed MTX clearance has been linked to an excess in MTX-induced toxicities. Glucarpidase is a recombinant enzyme that rapidly hydrolyzes MTX into non-toxic metabolites. The
Autor:
Cristina Matteo, Giovanni Schininà, Nunziatina Laura Parrinello, Roberta Sciortino, Salvatore Leotta, Giuseppe Milone, Gianna Maria Piccolo, Massimo Zucchetti, Francesco Di Raimondo, Maria Grazia Camuglia, Annalisa Condorelli, Maria Proietto
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:267-270
Relapse at the central nervous system (CNS) in acute myeloid leukemia (AML) carries a dismal prognosis. Treatment options are limited to intrathecal therapy, high-dose cytarabine, high-dose methotrexate, and radiotherapy. Novel strategies are needed.
Autor:
Dermot F. McGinnity, Diansong Zhou, Shringi Sharma, Buyun Chen, Venkatesh Pilla Reddy, Karthick Vishwanathan, Adrian J. Fretland, Joseph Ware, Yan Xu
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Limited information is available regarding the drug–drug interaction (DDI) potential of molecular targeted agents and rituximab plus cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone (R-CHOP) therapy
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Berzosertib (formerly M6620) is the first-in-class inhibitor of ataxia–telangiectasia and Rad3-related protein, a key component of the DNA damage response, and being developed in combination with chemotherapy for the treatment of patients w
Autor:
Long Yang, Zilin Cui, Jiancun Hou, Rui Shi, Yang Li, Zheyue Yuan, Qing Tian, Xiaolong Liu, Zirong Liu, Jian Wang, Yamin Zhang, Lianjiang Wang
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:125-134
The recurrence rate of hepatocellular carcinoma (HCC) after partial hepatectomy is still high. How to choose the most appropriate anti-tumor drug in the early postoperative period is crucial to improve the prognosis of patients. Recently, MiniPDX has
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:655-662
Small-molecule protein kinase inhibitors (PKIs) have substantially improved clinical outcomes of various diseases. However, some studies suggested these agents might induce acute kidney injury (AKI). This study was designed to comprehensively assess
Autor:
Taira Hada, Hiroaki Soyama, Soichiro Kakimoto, Takahiro Sakamoto, Hiroko Matsuura, Jin Suminokura, Morikazu Miyamoto, Hideki Iwahashi, Masashi Takano, Hiroki Ishibashi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 85:941-947
The aim of this study was to investigate the association between changes in the levels of vascular endothelial growth factors (VEGFs) after treatment with bevacizumab and gemcitabine (Bev-Gem) and the clinical outcome.Platinum-resistant ovarian cance
Autor:
Bhavana Pothuri, Jan H. Beumer, Joseph A. Sparano, Stephanie V. Blank, Mimi Kim, Dawn L. Hershman, Amy Tiersten, Leonard Liebes, Allison L. Brodsky, Franco M. Muggia, Brian F. Kiesel
Publikováno v:
Cancer Chemother Pharmacol
OBJECTIVE: Poly(ADP-Ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of DNA-damaging agents like doxorubicin. We sought to determine the recommended phase 2 dose (
Autor:
Kim Wai Yu, Laura Kruper, Yuan Yuan, Joanne E. Mortimer, Daphne Stewart, Louise Wong, Jae Jung, Samuel Chung, Sanjeet Dadwal, Jill Cooper
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose We update a patient series that reported a high incidence of infection with Gram-positive cocci in women treated with the combination of pertuzumab and trastuzumab and further characterize this clinical problem. Patients Treating physicians a